Year: 2026
Type: preprint
Abstract: External trial evidence can inform oncology trial design, but broad pooling may produce benchmarks poorly aligned with the planned population. We developed TRACE (Target-Trial Relevance Assessment and Compatibility-Guided Evidence Synthesis), combining eligibility screening, Bayesian compatibility assessment using published baseline characteristics, and hierarchical survival modeling. An integrated compatibility score based on the largest standardized difference in jointly reported characteristics identifies compatible external trials. Their reconstructed control-arm survival data are synthesized using a hierarchical beta-Stacy process to generate a predictive survival benchmark. We evaluated TRACE using eleven randomized phase III trials in first-line HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma. With KEYNOTE-859 as the target, three external trials were selected. TRACE predicted a control-arm median overall survival of 11.8 months (95% posterior predictive interval, 8.9-15.2), compared with an observed median of 11.8 months (95% confidence interval, 10.9-12.7). In leave-one-trial-out validation, seven targets had compatible external evidence. Predictive intervals contained the observed median for all seven. In comparison, confidence intervals from Kaplan-Meier estimates pooling all other trials' control arms contained it for five. Mean pointwise curve coverage was 92% for TRACE and 59% for pooled Kaplan-Meier. For four targets without compatible external evidence, TRACE returned a weakly informative prior predictive benchmark. TRACE provides a transparent approach to selecting relevant external evidence and generating benchmarks for oncology trial planning.
Source: arXiv (Cornell University)
Institutions: Yale Cancer Center, Yale University, Pfizer (United States)
Language: English
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Open Access status: green
OpenAlex ID: W7226021945
